Conference session discussed anticoagulation care, stroke prevention, and management of thromboembolic disorders. Managed care pharmacists involved in the care for patients at risk for thromboembolic ...

For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are ...

The 500 million international units (IUs) will include product specifically manufactured for donation allowing for a longer shelf life and enabling more people around the world to access life-saving ...

Chronic warfarin anticoagulation is commonly used to prevent thromboembolism in patients with atrial fibrillation or venous thromboembolism, and in the management of patients with mechanical heart ...

Atrial fibrillation (AF) greatly increases the risk ofstroke. Long-term oral therapy with warfarin reducesthe risk of AF-related stroke by 62%, and nationalguidelines now call for warfarin therapy in ...

Nat Clin Pract Gastroenterol Hepatol. 2006;3(1):24-32. Endoscopic therapy can be broadly categorized into injection therapy, thermal coagulation, and mechanical hemostasis. When analyzed separately, ...

This is the first and only randomised trial to show the superiority of longer duration over shorter duration of anticoagulation therapy for reducing thrombotic events in cancer patients with isolated ...

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia that significantly elevates the risk of thromboembolic events, most notably ischaemic stroke. Anticoagulation therapy has long been a ...

Please provide your email address to receive an email when new articles are posted on . Anticoagulants are one of the most commonly prescribed medication classes, and the utilization of these agents ...

VarmX and Rentschler Biopharma expand collaboration from early development to late‑stage and commercial manufacturing of VMX-C001 VMX‑C001 builds on strong regulatory momentum, including FDA Fast ...

Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, ...

Animal research protocols commonly require the use of anticoagulants in order to study a syndrome, prevent a common confounder, correct a spontaneous condition, or develop a novel treatment for humans ...